[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567893":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":36,"locations":42,"responsibleParty":61,"collaborators":31,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":31,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":31,"overallStatus":44,"whyStopped":31,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Empagliflozin 10mg","EXPERIMENTAL","Participants in this arm will take empagliflozin 10mg daily",[13],"Drug: Empagliflozin 10 mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants in this arm will take a placebo daily",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Empagliflozin 10 mg","For the empagliflozin arm, participants will take 10 mg daily.",[9],[27],"Jardiance",{"type":22,"name":15,"description":29,"armGroupLabels":30,"otherNames":31},"Participants in the placebo arm will take a placebo daily.",[15],null,[33],{"name":34,"affiliation":5,"role":35},"Hyon K Choi, MD, DrPH","PRINCIPAL_INVESTIGATOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":31,"email":41},"Ana D Fernandes, MA","CONTACT","617-643-2140","adfernandes@mgh.harvard.edu",[43],{"facility":5,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"RECRUITING","Boston","Massachusetts","02144","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-71.05977,42.35843,{"lat":54,"lon":53},[57],{"name":58,"role":39,"phone":59,"phoneExt":31,"email":60},"Hyon K Choi, MD","6177265650","hchoi@mgh.harvard.edu",{"type":35,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"Hyon Choi","Principal Investigator","100567893","phase-4-save-care-sodium-glucose-cotransporter-2-inhibitors-sglt2i-as-novel-gout-care-trial-100567893",false,"NCT06674109","SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial","SAVE-Care (SGLT2i As Novel Gout Care) Trial","SAVE-Care","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Provision of signed and dated informed consent form.\n2. Fulfilling American College of Rheumatology \\[ACR\\]\u002FEuropean Alliance of Associations for Rheumatology \\[EULAR\\] gout criteria\n3. 1+ gout flares in last 12 months\n4. Serum urate level ≥ 6mg\u002Fdl\n5. Males and females; Age 18-80\n6. Willingness to adhere to the study intervention procedures.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Estimated Glomerular Filtration Rate \\[eGFR\\] \\\u003C20ml\u002Fmin\n2. Colchicine or nonsteroidal anti-inflammatory drug \\[NSAID\\] prophylaxis\n3. active cardiovascular disease \\[CVD\\], type-1 diabetes\n4. pregnant and lactating women\n5. Presence of a condition(s) or diagnosis, either physical or psychological, or physical exam finding that precludes participation. \\[History of ketoacidosis, end-stage or decompensated liver disease, active cancer\\]\n6. Use of anti-obesity drugs\n7. Basal-bolus or multiple daily injection insulin regimens, or loop diuretics","ALL","18 Years","80 Years",{"count":76,"type":77},60,"ESTIMATED","INTERVENTIONAL",[80],"PHASE4","SAVE-Care (Sodium Glucose Cotransporter-2 inhibitors \\[SGLT2i\\] As Novel Gout Care) Trial is a double-blind randomized placebo-controlled trial (RCT) designed to assess the effect of empagliflozin on serum urate \\[SU\\] levels of gout patients, as well as levels of highly-sensitivity C-reactive protein \\[hsCRP\\] and interleukin 6 \\[IL-6\\], and estimate gout flares over 3 months, in order to develop a full-scale RCT of clinical endpoints to directly inform gout care guidelines.",[83],"Gout and Hyperuricemia","2026-06-01",{"date":86,"type":87},"2026-06-04","ACTUAL",{"date":89,"type":87},"2026-05-28",{"date":91,"type":77},"2028-02-28",{"name":5,"class":6},1]